Safety and efficacy of liraglutide 1.2mg in patients with mild and moderate renal impairment: The ABCD nationwide liraglutide audit

Practical Diabetes

Volumn 30, Issue 2, 2013, Pages 71-76b

  Thong, K Y ^a   Walton, C ^b   Ryder, R E J ^a  

^a CITY HOSPITAL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

GLP 1; Incretin; Liraglutide; Renal impairment

Indexed keywords

CREATININE; HEMOGLOBIN A1C; LIRAGLUTIDE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MULTICENTER STUDY; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84878324485     PISSN: None     EISSN: 20472900     Source Type: Journal    
DOI: 10.1002/pdi.1748     Document Type: Article

References (19)

1. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care 2011;Suppl 2:S279-84.
2. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1-5 studies. Diabetes Obes Metab 2009;11:26-34.
3. Jacobsen LV, et al. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009;68:898-905.
4. Linnebjerg H, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007;64:317-27.
5. Victoza (liraglutide injection) Prescribing Information. Available at: Www.novo-pi.com/victoza. pdf [accessed 3 August 2012].
6. Byetta (exenatide injection) Prescribing Information. Available at: Http://documents.byetta.com/Byetta-PI.pdf [accessed 3 October 2012].
7. Kaakeh Y, et al. Liraglutide-induced acute kidney injury. Pharmacotherapy 2012;32:e7-e11.
8. Weise WJ, et al. Exenatide-associated ischemic renal failure. Diabetes Care 2009;32:e22-e23.
9. Ryder REJ, et al. The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit. Pract Diabetes Int 2010;27:352-57b.
10. Joint Specialty Committee for Renal Disease, Royal College of Physicians of London and the Renal Association. Chronic kidney disease in adults: UK guidelines for identification, management and referral. Royal College of Physicians of London, 2006. Available at: Www.renal.org/ckdguide/full/ukckdfull. pdf [accessed 28 December 2012].
11. Zinman B, et al. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012;14: 77-82.
12. NICE technology appraisal guidance 203. Liraglutide for the treatment of type 2 diabetes. 2010. Available at: Http://guidance.nice.org.uk/TA203 [accessed 3 August 2012].
13. Davidson JA, et al. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 2010:1-31. [Epub ahead of print.]
14. Buse JB, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6). Lancet 2009;374:39-47.
15. Hendarto H, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase Amediated inhibition of renal NAD(P)H oxidases. Metabolism 2012. [Epub ahead of print.]
16. Liu WJ, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012;340: 248-55.
17. Stevens LA, et al. Advances in glomerular filtration rate estimating equations. Curr Opin Nephrol Hypertens 2010;19:298-307.
18. Chudleigh RA, et al. Influence of body weight on the performance of glomerular filtration rate estimators in subjects with type 2 diabetes. Diabetes Care 2008;31:47-9.
19. Nair S, et al. The four-variable modification of diet in renal disease formula underestimates glomerular filtration rate in obese type 2 diabetic individuals with chronic kidney disease. Diabetologia 2011; 54:1304-7.